Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

vasopressin (Rx)Brand and Other Names:Vasostrict, ADH

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injection solution

  • 20 units/mL
more...

Abdominal Distention

5 units IM initially; repeated q3-4hr PRN; may be increased to 10 units

Diabetes Insipidus

5-10 units IM/SC q8-12hr

Titrate dose on basis of serum sodium, serum osmolality, fluid balance, and urine output

Abdominal Roentgenography

10 units (0.5mL) IM/SC 2 hours before procedure, then 10 units IM 30 minutes before procedure

May give enema priotr to first dose of vasopressin

Dosage Modifications

Hepatic impairment: Lower doses may be required to achieve response

Gastrointestinal Hemorrhage (Off-label)

0.2-0.4 unit/min IV initially; may be increased to 0.8 unit/min IV PRN

Vasodilatory Shock (Off-label)

0.01-0.04 unit/min IV

Dosage Forms & Strengths

injection solution

  • 20 units/mL
more...

Abdominal Distention

Proportionately reduced adult dosage

Diabetes Insipidus

2.5-10 units IM/SC/intranasally q8-12hr

Continuous IV infusion: 0.0005 unit/kg/hr initially, then double dose q30min to reach desired effect; not to exceed 0.01 unit/kg/hr 

Titrate dose on basis of serum sodium, serum osmolality, fluid balance, and urine output

Gastrointestinal Hemorrhage (Off-label)

0.3 units/kg IV; not to exceed 20 units 

0.002-0.005 unit/kg/min IV initially; may be increased to 0.01 unit/kg/min IV PRN 

If bleeding controlled for 12-24 hr, taper off over 24-36 hr

Next

Interactions

Interaction Checker

vasopressin and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            Frequency Not Defined

            Abdominal cramps

            Allergic reaction

            Angina

            Bronchial constriction

            Circumoral pallor

            Diarrhea

            Nausea

            Pounding in the head

            Sweating

            Tremor

            Uterine contraction

            Vertigo

            Previous
            Next

            Warnings

            Contraindications

            Hypersensitivity

            Cautions

            With gastrointestinal (GI) bleeding, infusion should be continued for 12-24 hours after bleeding has stopped, and dosage should then be tapered over 24-48 hours

            Continuous infusion should be administered via controlled infusion device

            Use caution in chronic nephritis with nitrogen retention

            Pre- and postoperative patients with polyuria

            Use caution in patients with seizure, migraine, asthma, heart failure, vascular disease, angina pectoris, coronary thrombosis, renal disease

            Use in pregnant women only when clearly needed

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy category: C

            Lactation: Unknown whether drug is distributed into breast milk; use with caution

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Vasoconstrictor without inotropic or chronotopic effects; stimulates smooth muscle in GI tract to cause peristalsis

            Absorption

            Bioavailability: Destroyed by trypsin in GI tract; must be administered parenterally or intranasally

            Onset (antidiuretic activity): IM/SC, 2-8 hr

            Onset (pressor activity) IV, 30-60 min

            Metabolism

            Metabolized in liver and kidney; rapidly removed from plasma

            Elimination

            Half-life: 10-20 min (parenteral)

            Excretion: Urine (5-10%)

            Previous
            Next

            Administration

            IV Compatibilities

            Additive: Verapamil

            Y-site: Amiodarone, diltiazem, dobutamine, dopamine, epinephrine, heparin, lidocaine, milrinone, nitroglycerin, norepinephrine, phenylephrine, procainamide

            IV Preparation

            Infusion: Dilute to 0.1-1 unit/mL with NS or D5W

            IV/IM Administration

            Administered SC or IM or by continuous IV or intra-arterial infusion via controlled infusion device

            Storage

            Clear, colorless, or nearly colorless solution

            Unopened vials

            • Refrigerate at 2-8°C (36-46°F); do not freeze, OR
            • Controlled room temperature 20-25°C (68-77°F) for 12 months or manufacturer expiration date (whichever is earlier); do not store above 25°C (77°F)

            Opened vials (after first puncture)

            • Once opened, may store for 48 hr
            • Do not store above 25°C (77°F)
            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.